# CJC-1295 with DAC

Canonical source: https://retacompare.com/encyclopedia/cjc-1295-dac

Albumin-conjugated GHRH analog providing days-long elevation of GH and IGF-1 — distinct from the pulsatile pattern of native GHRH.

Reference facts

Also known asCJC-1295 DAC, Drug Affinity Complex GHRHCategoryGrowth Hormone & GhrelinMechanism of actionAlbumin-conjugated GHRH analog providing days-long elevation of GH and IGF-1 — distinct from the pulsatile pattern of native GHRH.TargetsGHRHRIndications under research or approvedOff-label researchRegulatory status (reference entry)Not FDA-approvedHalf-life~6–8 days (albumin-bound)SequenceYADAIFTNSYRKVLGQLSARKLLQDIMSRSequence notesCJC-1295 backbone with maleimidopropionyl-Lys30 that covalently conjugates to circulating albumin in vivo, extending half-life to ~6 days.Molecular weight (Da)3647First reported2005
    Primary References

Teichman et al., JCEM 2006


    Explore research articles about CJC-1295 with DAC


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Teichman et al., JCEM 2006: https://pubmed.ncbi.nlm.nih.gov/16352683/